- Report
- October 2026
- 375 Pages
Global
From €5401EUR$5,850USD£4,572GBP
- Report
- August 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- May 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4146EUR$4,490USD£3,509GBP
- Report
- September 2026
- 120 Pages
Global
From €7377EUR$7,990USD£6,244GBP
- Report
- August 2026
- 106 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 70 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 160 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- July 2026
- 160 Pages
Global
From €4386EUR$4,750USD£3,712GBP
- Report
- August 2026
- 160 Pages
Global
From €3065EUR$3,320USD£2,595GBP
€3832EUR$4,150USD£3,243GBP
- Report
- July 2026
- 160 Pages
Global
From €3065EUR$3,320USD£2,595GBP
€3832EUR$4,150USD£3,243GBP
- Report
- July 2026
- 160 Pages
Global
From €3065EUR$3,320USD£2,595GBP
€3832EUR$4,150USD£3,243GBP
- Report
- August 2026
- 100 Pages
Latin America
From €4386EUR$4,750USD£3,712GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2308EUR$2,500USD£1,954GBP

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. It is a member of the Endocrine and Metabolic Disorders Drugs class, which are used to treat a variety of conditions related to hormones and metabolism. Lixisenatide works by stimulating the release of insulin from the pancreas, helping to reduce blood sugar levels. It is typically used in combination with other diabetes medications, such as metformin or sulfonylureas.
Lixisenatide is available in both injectable and oral formulations. The injectable form is administered once daily, while the oral form is taken once weekly. Common side effects of lixisenatide include nausea, diarrhea, and headache. It is important to note that lixisenatide should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
Some companies in the Lixisenatide market include Sanofi, Eli Lilly, and Novo Nordisk. Show Less Read more